₿$70,645.00▼ 3.31%
Atai Beckley N.V.
ATAI🇳🇱Reserve
ATAI Life Sciences N.V. (now Atai Beckley N.V.) is a clinical-stage biopharmaceutical company developing transformative mental health treatments. In March 2025, the company allocated $5M of existing cash reserves to purchase Bitcoin as a treasury diversification strategy.
BTC Holdings
99 BTC
Insufficient history
Stock Price
$3.64
180d
Total financing
0.00 USD
Insufficient history
mNAV
189.03x
180d
BTC Credit
0 bps>10x
Sats/Share
27
180d
Mkt cap
1.32B USD
Shares
363.19M
Fiat reserve
30.40M USD
Total reserve
37.40M USD
Leverage
0.0%
Dilution
0.0%
Analytics
Financials
US-GAAPQuarterlyAs of 2025-09-30
Balance Sheet
Total Assets$239.8M▲26.8%
Total Liabilities$79.9M▲76.5%
Stockholders' Equity$159.9M▲11.2%
Cash & Equivalents$30.4M▼50.9%
Total Debt$0
Digital Assets$11.4M▲83.1%
Income Statement
Revenue$749K▲4.2%
Operating Income$-28.4M▼12.5%
Net Income$-61.1M▼120.3%
Interest Expense$0▼100.0%
Cash Flow
Operating Cash Flow$-23.3M▲27.2%
Instruments
Recent Changes
Mon, Nov 10, 2025
Shares Outstanding
240.4M→363.2M+122.8M(+51.1%)
Post-Q3: includes 27,283,750 public offering shares (Oct 20) and ~95.5M Beckley Psytech acquisition shares (Nov 5)
Form 10-Q (Q3 2025)